Predicting the impact of new pneumococcal conjugate vaccines: serotype composition is not enough

References

• Klugman KP , Cutts F , Adegbola RA , et al. Meta-analysis of the efficacy of conjugate vaccines against invasive pneumococcal disease. In: Siber GR , Klugman KP , Mäkelä PH , editors. Pneumococcal vaccines: the impact of conjugate vaccine. ASM Press; Washington, DC, USA: 2008
   Google Scholar
• Taylor S , Marchisio P , Vergison A , et al. Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. Clin Infect Dis 2012;54(12):1765-73
   PubMed Web of Science ®Google Scholar
• Fitzwater SP , Chandran A , Santosham M , Johnson HL . The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2012;31(5):501-8
   PubMed Web of Science ®Google Scholar
• Feikin DR , Kagucia EW , Loo JD , et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med 2013;10(9):e1001517
   PubMed Web of Science ®Google Scholar
• Pilishvili T , Lexau C , Farley MM , et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201(1):32-41
   PubMed Web of Science ®Google Scholar
• Pneumococcal vaccines WHO position paper –. 2012. Wkly Epidemiol Rec 2012;87(14):129-44
   PubMedGoogle Scholar
• Hausdorff WP , Bryant J , Paradiso PR , Siber GR . Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000;30(1):100-21
   PubMed Web of Science ®Google Scholar
• Wroe PC , Lee GM , Finkelstein JA , et al. Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine. Pediatr Infect Dis J 2012;31(3):249-54
   PubMed Web of Science ®Google Scholar
• Hausdorff WP , Fierens F , Hoet B . Efficacy and effectiveness of PHiD-CV against invasive pneumococcal disease and pneumonia: recent data. Presented at Nordic Vaccine Meeting; 5 – 7 September 2012; Copenhagen, Denmark
   Google Scholar
• Andrews N , Waight PA , Borrow R , et al. Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales. PLoS One 2011;6(12):e28435
   PubMed Web of Science ®Google Scholar
• Palmu AA , Jokinen J , Nieminen H , et al. Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial. Lancet Resp Med 2014; doi: 10.1016/S2213-2600(14)70139-0. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Lee H , Choi EH , Lee HJ . Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines. Korean J Pediatr 2014;57(2):55-66
   PubMedGoogle Scholar
• Black SB , Shinefield HR , Ling S , et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002;21(9):810-15
   PubMed Web of Science ®Google Scholar
• Eskola J , Kilpi T , Palmu A , et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001;344(6):403-9
   PubMed Web of Science ®Google Scholar
• Whitney CG , Pilishvili T , Farley MM , et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006;368(9546):1495-502
   PubMed Web of Science ®Google Scholar
• Bettinger JA , Scheifele DW , Kellner JD , et al. The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine 2010;28(9):2130-6
   PubMed Web of Science ®Google Scholar
• Kieninger DM , Kueper K , Steul K , et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 2010;28(25):4192-203
   PubMed Web of Science ®Google Scholar
• Vesikari T , Wysocki J , Chevallier B , et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009;28(4 Suppl):S66-76
   PubMed Web of Science ®Google Scholar
• Miller E , Andrews NJ , Waight PA , et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011;11(10):760-8
   PubMed Web of Science ®Google Scholar
• De Wals P , Lefebvre B , Markowski F , et al. Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada. Vaccine 2014;32(13):1501-6
   PubMed Web of Science ®Google Scholar
• Andrews NJ , Waight PA , Burbidge P , et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis 2014;14(9):839-46
   PubMed Web of Science ®Google Scholar
• Cutts FT , Zaman SM , Enwere G , et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005;365(9465):1139-46
   PubMed Web of Science ®Google Scholar
• Klugman KP , Madhi SA , Huebner RE , et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003;349(14):1341-8
   PubMed Web of Science ®Google Scholar
• Hausdorff WP , Feikin DR , Klugman KP . Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005;5(2):83-93
   PubMed Web of Science ®Google Scholar
• Yaro S , Lourd M , Traore Y , et al. Epidemiological and molecular characteristics of a highly lethal pneumococcal meningitis epidemic in Burkina Faso. Clin Infect Dis 2006;43(6):693-700
   PubMed Web of Science ®Google Scholar
• Lipsitch M , Whitney CG , Zell E , et al. Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease? PLoS Med 2005;2(1):e15
   PubMed Web of Science ®Google Scholar
• Heffron R . Pneumonia: with special reference to Pneumococcus lobar pneumonia. Commonwealth Fund; Cambridge, London, UK: 1939
   Google Scholar
• Butler JC , Breiman RF , Campbell JF , et al. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993;270(15):1826-31
   PubMed Web of Science ®Google Scholar
• Singleton RJ , Butler JC , Bulkow LR , et al. Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska native adults. Vaccine 2007;25(12):2288-95
   PubMed Web of Science ®Google Scholar
• Klugman KP , Madhi SA , Adegbola RA , et al. Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose. Vaccine 2011;29(18):3372-3
   PubMed Web of Science ®Google Scholar
• Miller E , Andrews NJ , Waight PA , et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011;29(49):9127-31
   PubMed Web of Science ®Google Scholar
• Andrews NJ , Waight PA , George RC , et al. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 2012;30(48):6802-8
   PubMed Web of Science ®Google Scholar
• Prymula R , Peeters P , Chrobok V , et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006;367(9512):740-8
   PubMed Web of Science ®Google Scholar
• Puumalainen T , Dagan R , Wuorimaa T , et al. Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants. Pediatr Infect Dis J 2003;22(2):141-9
   PubMed Web of Science ®Google Scholar
• Togashi T , Yamaji M , Thompson A , et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan. Pediatr Infect Dis J 2013;32(9):984-9
   PubMed Web of Science ®Google Scholar
• Poolman J , Kriz P , Feron C , et al. Pneumococcal serotype 3 otitis media, limited effect of polysaccharide conjugate immunisation and strain characteristics. Vaccine 2009;27(24):3213-22
   PubMed Web of Science ®Google Scholar
• Dagan R , Patterson S , Juergens C , et al. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis 2013;57(7):952-62
   PubMed Web of Science ®Google Scholar
• Steens A , Bergsaker MA , Aaberge IS , et al. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 2013;31(52):6232-8
   PubMed Web of Science ®Google Scholar
• Harboe ZB , Dalby T , Weinberger DM , et al. Impact of 13-valent conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis 2014. doi: 10.1093/cid/ciu524. [Epub ahead of print]
   Web of Science ®Google Scholar
• Demczuk WH , Martin I , Griffith A , et al. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. Can J Microbiol 2013;59(12):778-88
   PubMed Web of Science ®Google Scholar
• JCVI pneumococcal sub-committee meeting. Available from: http://media.dh.gov.uk/network/261/files/2012/07/JCVI-minutes-Pneumococcal-sub-committee-meeting-held-on-30-May-2012.pdf [Last accessed 7 March 2014]
   Google Scholar
• Millar EV , O’Brien KL , Bronsdon MA , et al. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine. Clin Infect Dis 2007;44(9):1173-9
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW , Saez-Llorens X , Lopez P , et al. for the COMPAS Group . Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med 2014;11(6):e1001657
   PubMed Web of Science ®Google Scholar
• Kilpi T , Ahman H , Jokinen J , et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin Infect Dis 2003;37(9):1155-64
   PubMed Web of Science ®Google Scholar
• Jokinen JT , Ahman H , Kilpi TM , et al. Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media. J Infect Dis 2004;190(3):545-50
   PubMed Web of Science ®Google Scholar
• De Wals P , Erickson L , Poirier B , et al. How to compare the efficacy of conjugate vaccines to prevent acute otitis media? Vaccine 2009;27(21):2877-83
   PubMed Web of Science ®Google Scholar
• Alpert HR , Behm I , Connolly GN , Kabir Z . Smoke-free households with children and decreasing rates of paediatric clinical encounters for otitis media in the United States. Tob Control 2011;20(3):207-11
   PubMed Web of Science ®Google Scholar
• Lucero MG , Dulalia VE , Nillos LT , et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009(4):CD004977
   PubMed Web of Science ®Google Scholar
• Loo JD , Conklin L , Fleming-Dutra KE , et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia. Pediatr Infect Dis J 2014;33(Suppl 2):S140-51
   PubMed Web of Science ®Google Scholar
• Hausdorff WP , Dagan R . Serotypes and pathogens in paediatric pneumonia. Vaccine 2008;26 Suppl 2:B19-23
   PubMed Web of Science ®Google Scholar
• Root ED , Lucero M , Nohynek H , et al. Distance to health services affects local-level vaccine efficacy for pneumococcal conjugate vaccine (PCV) among rural Filipino children. Proc Natl Acad Sci USA 2014;111(9):3520-5
   PubMed Web of Science ®Google Scholar
• Henrichsen J . Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 1995;33(10):2759-62
   PubMed Web of Science ®Google Scholar
• Robbins JB , Austrian R , Lee CJ , et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983;148(6):1136-59
   PubMed Web of Science ®Google Scholar
• Foster D , Walker AS , Paul J , et al. Reduction in invasive pneumococcal disease following implementation of the conjugate vaccine in the Oxfordshire region, England. J Med Microbiol 2011;60(Pt 1):91-7
   PubMed Web of Science ®Google Scholar
• Park IH , Moore MR , Treanor JJ , et al. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis 2008;198(12):1818-22
   PubMed Web of Science ®Google Scholar
• Richter SS , Heilmann KP , Dohrn CL , et al. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011. Emerg Infect Dis 2013;19(7):1074-83
   PubMed Web of Science ®Google Scholar
• Siber GR , Chang I , Baker S , et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007;25(19):3816-26
   PubMed Web of Science ®Google Scholar
• Dagan R , Givon-Lavi N , Porat N , Greenberg D . The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial. Vaccine 2012;30(34):5132-40
   PubMed Web of Science ®Google Scholar
• O’Brien KL , Millar EV , Zell ER , et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis 2007;196(8):1211-20
   PubMed Web of Science ®Google Scholar
• Grivea IN , Tsantouli AG , Michoula AN , Syrogiannopoulos GA . Dynamics of Streptococcus pneumoniae nasopharyngeal carriage with high heptavalent pneumococcal conjugate vaccine coverage in Central Greece. Vaccine 2011;29(48):8882-7
   PubMed Web of Science ®Google Scholar
• Ho PL , Chiu SS , Chan MY , et al. Changes in nasopharyngeal carriage and serotype distribution of antibiotic-resistant Streptococcus pneumoniae before and after the introduction of 7-valent pneumococcal conjugate vaccine in Hong Kong. Diagn Microbiol Infect Dis 2011;71(4):327-34
   PubMed Web of Science ®Google Scholar
• Ekström N , Haikala R , Lehtonen H , et al. Functional activity of antibodies to pneumococcal serotypes 6A and 19A in the Finnish Otitis Media (FinOM) Vaccine Trial. Presented at 4th International Symposium on Pneumococci and Pneumococcal Diseases; 9 – 13 May 2004; Helsinki, Finland
   Google Scholar
• Wysocki J , Tejedor JC , Grunert D , et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different Neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J 2009;28(4 Suppl):S77-88
   PubMed Web of Science ®Google Scholar
• SIREVA II . Available from: http://www.paho.org/hq/index.php?option=com_content&view=category&layout=blog&id=3609&Itemid=3953&lang=pt [Last accessed 7 March 2014]
   Google Scholar
• McEllistrem MC , Nahm MH . Novel pneumococcal serotypes 6C and 6D: anomaly or harbinger. Clin Infect Dis 2012;55(10):1379-86
   PubMed Web of Science ®Google Scholar
• Kuch A , Sadowy E , Skoczynska A , Hryniewicz W . First report of Streptococcus pneumoniae serotype 6D isolates from invasive infections. Vaccine 2010;28(39):6406-7
   PubMed Web of Science ®Google Scholar
• Cooper D , Yu X , Sidhu M , et al. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine 2011;29(41):7207-11
   PubMed Web of Science ®Google Scholar
• Hausdorff WP , Hoet B , Schuerman L . Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr 2010;10:4
   PubMed Web of Science ®Google Scholar
• Hicks LA , Harrison LH , Flannery B , et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007;196(9):1346-54
   PubMed Web of Science ®Google Scholar
• Poolman J , Frasch C , Nurkka A , et al. Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines. Clin Vaccine Immunol 2011;18(2):327-36
   PubMed Web of Science ®Google Scholar
• Mrkvan T , Hoet B , Adegbola RA , et al. Serotype 19A and the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV): lessons learned to date. Presented at 31st Meeting of the European Society for Paediatric Infectious Diseases; 28 May – 1 June 2013; Milan, Italy
   Google Scholar
• de Wals P , Lefebvre B , Defay F , et al. Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada. Vaccine 2012;30(45):6416-20
   PubMed Web of Science ®Google Scholar
• Kilpi T , Palmu AA , Ruokokoski E , et al. Indirect impact of pneumococcal Haemophilus influenzae protein-D conjugate vaccine (PHID-CV10) on invasive pneumococcal disease (IPD) in a clinical trial. Presented at 8th World Congress on Pediatric Infectious Diseases; 19 – 22 November 2013; Cape Town, South Africa
   Google Scholar
• Invasive pneumococcal disease reports in New Zealand. Available from: https://surv.esr.cri.nz/surveillance/IPD.php [Last accessed 7 March 2014]
   Google Scholar
• Impact of 10-valent pneumococcal conjugate vaccine (PCV10) against invasive pneumococcal disease (IPD) among vaccine-eligible children in Finland. Available from: http://www.slideshare.net/THLfi/ip-ddirect-nvpwspid2013finland [Last accessed March7 2014]
   Google Scholar
• Quebec: INSPQ Annual surveillance report 2010. Available from: http://www.inspq.qc.ca/pdf/publications/1383_ProgSurvPneumocoque2010.pdf [Last accessed 7 March 2014]
   Google Scholar
• Domingues CMAS , Verani JR , Montenegro ER , et al. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study Lancet Resp Med. 2014; in press
   Google Scholar
• de Wals P . Invasive pneumococcal disease in two birth cohorts vaccinated, respectively, with 2+1 PCV-7 or PHiD-CV-10 doses. Presented at 8th International Symposium on Pneumococci and Pneumococcal Diseases; 11 – 15 March 2012; Iguaçu Falls, Brazil
   Google Scholar
• Moore M , Taylor T , Pondo T , et al. Impact of 13-valent pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease (IPD) among children <5 years old in the U.S. Pneumonia 2014;3:149
   Google Scholar
• Simell B , Auranen K , Kayhty H , et al. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines 2012;11(7):841-55
   PubMed Web of Science ®Google Scholar
• Hausdorff WP , Brueggemann AB , Hackell JG , Scott JA . Pneumococcal serotype epidemiology. In: Siber GR , Klugman KP , Mäkelä PH , editors. Pneumococcal Vaccines: the impact of conjugate vaccine. ASM Press; Washington, DC, USA: 2008
   Google Scholar
• van den Bergh MR , Spijkerman J , Swinnen KM , et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis 2013;56(3):e30-9
   PubMed Web of Science ®Google Scholar
• Van Effelterre T , Moore MR , Fierens F , et al. A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination. Vaccine 2010;28(21):3650-60
   PubMed Web of Science ®Google Scholar
• Brandileone MCC , Almeida SCG , Zanella RC , et al. Effect of PCV10 vaccination on pneumococcal serotypes in Brazil using the national pneumococcal laboratory network surveillance. Pneumonia 2014;3:158
   Google Scholar
• Vesikari T , Forstén A , Seppä I , et al. Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage in Finnish children: a cluster-randomised controlled trial. Presented at 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 27 – 30 April 2013; Berlin, Germany
   Google Scholar
• Weinberger DM , Malley R , Lipsitch M . Serotype replacement in disease after pneumococcal vaccination. Lancet 2011;378(9807):1962-73
   PubMed Web of Science ®Google Scholar
• van Gils EJ , Veenhoven RH , Hak E , et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA 2009;302(2):159-67
   PubMed Web of Science ®Google Scholar
• Cohen R , Levy C , Bonnet E , et al. Dynamic of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 introduction in France. Vaccine 2010;28(37):6114-21
   PubMed Web of Science ®Google Scholar
• Huang SS , Hinrichsen VL , Stevenson AE , et al. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics 2009;124(1):e1-11
   PubMed Web of Science ®Google Scholar
• Vestrheim DF , Hoiby EA , Aaberge IS , Caugant DA . Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway. Clin Vaccine Immunol 2010;17(3):325-34
   PubMed Web of Science ®Google Scholar
• Prymula R , Hanovcova I , Splino M , et al. Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage. Vaccine 2011;29(10):1959-67
   PubMed Web of Science ®Google Scholar
• Russell FM , Carapetis JR , Satzke C , et al. Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster. Clin Vaccine Immunol 2010;17(12):1970-6
   PubMed Web of Science ®Google Scholar
• Roca A , Hill PC , Townend J , et al. Effects of community-wide vaccination with PCV-7 on pneumococcal nasopharyngeal carriage in the Gambia: a cluster-randomized trial. PLoS Med 2011;8(10):e1001107
   PubMed Web of Science ®Google Scholar
• Nzenze SA , Shiri T , Nunes MC , et al. Temporal changes in pneumococcal colonization in a rural African community with high HIV prevalence following routine infant pneumococcal immunization. Pediatr Infect Dis J 2013;32(11):1270-8
   PubMed Web of Science ®Google Scholar
• Yeh SH , Zangwill KM , Lee H , et al. Heptavalent pneumococcal vaccine conjugated to outer membrane protein of Neisseria meningitidis serogroup b and nasopharyngeal carriage of Streptococcus pneumoniae in infants. Vaccine 2003;21(19-20):2627-31
   PubMed Web of Science ®Google Scholar
• Dagan R , Melamed R , Muallem M , et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996;174(6):1271-8
   PubMed Web of Science ®Google Scholar
• Sáez-Llorens X , Wong D , Rodríguez M , et al. Effect of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccines (PHiD-CV) on nasopharyngeal bacterial carriage in Panamanian children. Presented at 7th World Congress of the World Society for Pediatric Infectious Diseases; 16 – 19 November 2011; Melbourne, Australia
   Google Scholar
• Weinberger DM , Harboe ZB , Flasche S , et al. Prediction of serotypes causing invasive pneumococcal disease in unvaccinated and vaccinated populations. Epidemiology 2011;22(2):199-207
   PubMed Web of Science ®Google Scholar
• Weinberger DM , Bruden DT , Grant LR , et al. Using pneumococcal carriage data to monitor postvaccination changes in invasive disease. Am J Epidemiol 2013;178(9):1488-95
   PubMed Web of Science ®Google Scholar
• Nurhonen M , Auranen K . Optimal serotype compositions for Pneumococcal conjugate vaccination under serotype replacement. PLoS Comput Biol 2014;10(2):e1003477
   PubMed Web of Science ®Google Scholar
• Hsu HE , Shutt KA , Moore MR , et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009;360(3):244-56
   PubMed Web of Science ®Google Scholar
• Cohen AL , Harrison LH , Farley MM , et al. Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. AIDS 2010;24(14):2253-62
   PubMed Web of Science ®Google Scholar
• Madhi SA , Klugman KP . A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004;10(8):811-13
   PubMed Web of Science ®Google Scholar
• Dunne EM , Smith-Vaughan HC , Robins-Browne RM , et al. Nasopharyngeal microbial interactions in the era of pneumococcal conjugate vaccination. Vaccine 2013;31(19):2333-42
   PubMed Web of Science ®Google Scholar
• Barkai G , Leibovitz E , Givon-Lavi N , Dagan R . Potential contribution by nontypable Haemophilus influenzae in protracted and recurrent acute otitis media. Pediatr Infect Dis J 2009;28(6):466-71
   PubMed Web of Science ®Google Scholar
• Jokinen J , Palmu AA , Kilpi T . Acute otitis media replacement and recurrence in the Finnish otitis media vaccine trial. Clin Infect Dis 2012;55(12):1673-6
   PubMed Web of Science ®Google Scholar
• Borys D , Saéz-Llorens X , Prymula R , et al. 10- and 11-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccines (PHiD-CV and 11PN-PD) on nasopharyngeal bacterial carriage. Presented at 8th International Symposium on Pneumococci and Pneumococcal Diseases; 11 – 15 March 2012; Iguaçu Falls, Brazil
   Google Scholar
• Deceuninck G , De Wals P . Effectiveness of three pneumococcal conjugate vaccines (PCVs) to prevent invasive pneumococcal disease (IPD) in Quebec, Canada. Pneumonia 2014;3:163
   Google Scholar
• Nurkka A , Ahman H , Yaich M , et al. Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncT. Vaccine 2002;20(1-2):194-201
   Web of Science ®Google Scholar
• Prince Valdemar of Denmark, Wikipedia. Available from: http://en.wikipedia.org/wiki/Prince_Valdemar_of_Denmark
   Google Scholar
• Bacterial Meningitis in the Netherlands: annual Reports for 2010 and 2012. Available from: www.amc.nl/web/Research/Departments/Overview/Medical-Microbiology/Medical-Microbiology/Current-research/Reference-Laboratory-for-Bacterial-Meningitis.htm?print=true [Last accessed 7 March 2014]
   Google Scholar